Serum Beta-Secretase 1 Activity Is a Potential Marker for the Differential Diagnosis between Alzheimer’s Disease and Frontotemporal Dementia: A Pilot Study-Reference-Cited by-同舟云学术

Serum Beta-Secretase 1 Activity Is a Potential Marker for the Differential Diagnosis between Alzheimer’s Disease and Frontotemporal Dementia: A Pilot Study

Published:2024-07-30 Issue:15 Volume:25 Page:8354
ISSN:1422-0067
Container-title:International Journal of Molecular Sciences
language:en
Short-container-title:IJMS

Author:

Saraceno Claudia¹^ORCID,Cervellati Carlo²^ORCID,Trentini Alessandro³^ORCID,Crescenti Daniela¹^ORCID,Longobardi Antonio¹^ORCID,Geviti Andrea⁴^ORCID,Bonfiglio Natale Salvatore⁴,Bellini Sonia¹^ORCID,Nicsanu Roland¹^ORCID,Fostinelli Silvia⁵^ORCID,Mola Gianmarco²,Riccetti Raffaella³,Moretti Davide Vito⁶,Zanetti Orazio⁷,Binetti Giuliano⁵,Zuliani Giovanni²,Ghidoni Roberta¹^ORCID

Affiliation:

1. Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy

2. Department of Translational Medicine and for Romagna, University of Ferrara, 44121 Ferrara, Italy

3. Department of Environmental and Prevention Sciences, University of Ferrara, 44121 Ferrara, Italy

4. Service of Statistics, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy

5. MAC–Memory Clinic and Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy

6. Alzheimer’s Rehabilitation Operative Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy

7. Alzheimer’s Research Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy

Abstract

Alzheimer’s disease (AD) and frontotemporal dementia (FTD) are the two major neurodegenerative diseases causing dementia. Due to similar clinical phenotypes, differential diagnosis is challenging without specific biomarkers. Beta-site Amyloid Precursor Protein cleaving enzyme 1 (BACE1) is a β-secretase pivotal in AD pathogenesis. In AD and mild cognitive impairment subjects, BACE1 activity is increased in brain/cerebrospinal fluid, and plasma levels appear to reflect those in the brain. In this study, we aim to evaluate serum BACE1 activity in FTD, since, to date, there is no evidence about its role. The serum of 30 FTD patients and 30 controls was analyzed to evaluate (i) BACE1 activity, using a fluorescent assay, and (ii) Glial Fibrillary Acid Protein (GFAP) and Neurofilament Light chain (NfL) levels, using a Simoa kit. As expected, a significant increase in GFAP and NfL levels was observed in FTD patients compared to controls. Serum BACE1 activity was not altered in FTD patients. A significant increase in serum BACE1 activity was shown in AD vs. FTD and controls. Our results support the hypothesis that serum BACE1 activity is a potential biomarker for the differential diagnosis between AD and FTD.

Funder

Italian Ministry of Health, Italy

Publisher

MDPI AG

Link

https://www.mdpi.com/1422-0067/25/15/8354/pdf

Reference76 articles.

1. (2024, July 22). Global Action Plan on the Public Health Response to Dementia. Available online: https://www.who.int/publications/i/item/global-action-plan-on-the-public-health-response-to-dementia-2017---2025.

2. (2024). 2024 Alzheimer’s Disease Facts and Figures. Alzheimers Dement., 20, 3708–3821.

3. Adam, M.P., Feldman, J., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Gripp, K.W., and Amemiya, A. (1993). Alzheimer Disease Overview. GeneReviews®, University of Washington.

4. (2021). 2021 Alzheimer’s Disease Facts and Figures. Alzheimers Dement., 17, 327–406.

5. The Prevalence and Incidence of Frontotemporal Dementia: A Systematic Review;Hogan;Can. J. Neurol. Sci.,2016